Unfortunately, amongst the regulators identified in the CSF1R-regulating GRN, few display a propensity to be suitable therapeutic targets in epilepsy, either because no drug crossing the blood-brain barrier are available, or because their safety profile and lack of specificity would hamper their use in chronic administration. Here, GRN is linked to epilepsy.